Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo; Ipilimumab, Yervoy) versus observation

Postoperative adjuvant radio chemo therapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk

Cabozantinib in advanced adrenocortical carcinoma progressing after standard therapy (CaboACC)

Randomisierte, zweiarmige, nicht vergleichende Phase II Studie zur Wirksamkeit von Atezolizumab und Roche Bevacizumab (Atezo/Bev) gefolgt von selektiver TACE nur bei Bedarf (sdTACE) im Falle des Auftretens von Krankheitsprogression oder initial synchroner Behandlung mit TACE und Atezo/Bev auf die 24-Monate-Überlebensrate bei der Behandlung von Patienten mit nicht resektablem hepatozellulärem Karzinom (DEMAND)

Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic AIO-KRK/YMO-0519

Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort study

Anti-hormonelle Erhaltungstherapie mit oder ohne den CDK 4/6 Inhibitor Riboclib nach Erstlinien-Chemotherapy bei Patienten mit Hormon Rezeptor-positiven und HER2neu negativen Brustkrebs.

Perioperative/Adjuvant atezolizumab with or without the immunomodulatory IMM-101 in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a randomized Phase II study

A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)